期刊
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY
卷 48, 期 -, 页码 425-461出版社
ANNUAL REVIEWS
DOI: 10.1146/annurev.pharmtox.48.113006.094847
关键词
coreceptor; CCR5; therapy; prevention; microbicide; resistance
资金
- NIAID NIH HHS [R01 AI 41420, P01 AI 51649, R21 AI 071935] Funding Source: Medline
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI071935, R01AI041420, P01AI051649] Funding Source: NIH RePORTER
Since the identification of CCR5 and CXCR4 as HIV coreceptors a little over a decade ago, there has been hope that coreceptor inhibitors will be able to make an impact on the HIV epidemic, both as novel therapeutic drugs and as agents used in prevention. Significant progress has been made in the understanding of how coreceptor choice might impact HIV pathology and how coreceptor blockade may affect health. In this review, we focus on some of the key issues that are emerging now that CCR5 has been validated as a promising target for HIV prevention strategies and at a time when a CCR5 inhibitor has been approved in the United States as the first in a new class of anti-HIV therapeutic drugs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据